Medical News

RSS

Emdeon's Assistant, Claim Master solutions earn HFMA Peer Reviewed designation

Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced that its automated patient eligibility and benefits verification tool, Emdeon® Assistant™, and web-based billing management solution, Emdeon Claim Master®, have earned the Peer Reviewed designation of the Healthcare Financial Management Association (HFMA). The HFMA Peer Reviewed designation places these Emdeon solutions on a short list of prestigious products that have been proven effective by industry expert volunteers and independent HFMA staff.

21 Jun 2010

Saladax Biomedical, Bristol-Myers Squibb collaborate to develop clinical diagnostics

Saladax Biomedical, Inc. announced today that it has entered into a multi-year development and commercialization agreement with Bristol-Myers Squibb Company for the development of certain clinical diagnostic tests to be used in conjunction with the development of certain therapeutic compounds in the Bristol-Myers Squibb pipeline.

21 Jun 2010

First StemSource Cell Bank in U.S. open

BioLife Cell Bank, LLC has opened the first U.S. StemSource® Cell Bank, which offers patients a way to safely and affordably store their own adipose (fat) tissue or their own naturally occurring adipose (fat) tissue-derived stem and regenerative cells. This gives patients and physicians easy, multi-use access to cells and tissue for future approved or allowed reconstructive fat grafting or augmentation procedures using the patients' own cells and/or tissue.

21 Jun 2010

Dako, Omnyx partner to develop clinical algorithms for digital pathology

Dako, a Danish-based world leader in tissue-based cancer diagnostics, and Omnyx, a leader in digital pathology solutions, announced today that they have entered into a three-year agreement to develop clinical algorithms for digital pathology. The aim is to support pathologists in generating even more accurate, objective and reproducible diagnostic results.

21 Jun 2010

Simulations Plus third-quarter consolidated preliminary revenues up 14.9% to $3.1M

Simulations Plus, Inc., a leading provider of software for pharmaceutical discovery and development, today released preliminary revenues for its third fiscal quarter ended May 31, 2010.

21 Jun 2010

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

Essen BioScience Inc. - a specialty provider of cell-based assay solutions and contract research services - and Nycomed - a privately owned global pharmaceutical company headquartered in Zurich, Switzerland - are pleased to announce a joint discovery agreement to identify novel small molecule ion channel modulators as pain therapeutics.

From Sartorius 21 Jun 2010

FDA grants Pathway 510(k) clearance for JETSTREAM G3 SF peripheral revascularization catheter for PVD

Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced that the U.S. Food & Drug Administration (FDA) has granted the company 510(k) clearance to market JETSTREAM G3™ SF (Small Fixed), the newest version of its peripheral revascularization catheter for the treatment of PVD.

21 Jun 2010

LIVALO for primary hyperlipidemia or mixed dyslipidemia now available in U.S.

Kowa Pharmaceuticals America, Inc., and Eli Lilly and Company today announced that LIVALO® (pitavastatin) tablets is now available in retail pharmacies throughout the United States. LIVALO, a statin medication approved by the U.S. Food and Drug Administration (FDA) in August 2009 is indicated for adults as an adjunctive therapy to diet for the treatment of primary hyperlipidemia or mixed dyslipidemia. LIVALO is available in doses of 1 mg, 2 mg and 4 mg.

21 Jun 2010

AMRI board approves new $10 million share repurchase program

AMRI today announced that its board of directors has approved a new share repurchase program of up to $10 million. Under the program, the company is authorized to repurchase outstanding shares of its Common Stock in the open market or in private transactions. Shares may be repurchased from time to time and in such amounts as market conditions warrant, subject to price ranges set by management and regulatory considerations.

21 Jun 2010

Electron cryomicroscopy helps observe molecules in hydrated state close to natural state

Gene expression takes place in two stages: the transcription of DNA to RNA by an enzyme called RNA polymerase, , followed by the translation of this RNA into proteins, whose behaviour affects the characteristics of each individual.

21 Jun 2010

MDT aligned with AAP position statement on efforts to be made to save patient's natural dentition

Millennium Dental Technologies, Inc. (MDT), pioneers of the patented LANAP™ protocol for the treatment of gum disease and the manufacturer of the PerioLase® MVP-7™ digital dental laser, are aligned with the American Academy of Periodontology (AAP) position statement that "efforts should be made to save a patient's natural dentition."

21 Jun 2010

Families of children with cancer are visiting Capitol Hill to seek more federal funding for cancer research

Today and tomorrow hundreds of families of children with cancer are visiting Capitol Hill to ask Congress one question: Where is the research money that was authorized by the Caroline Pryce Walker Conquer Childhood Cancer Act of 2008?

21 Jun 2010

Antibacterial lab coats to help prevent spread of disease in hospitals

According to the Centers for Disease Control and Prevention, 99,000 people die every year from infections acquired while in hospitals. "The goal in our profession is to help cure you not introduce you to another deadly infection," said Dr. Charles Kinder, Heart Rhythm expert and Director of Heart Rhythm Program at Heart Care Centers of Illinois.

21 Jun 2010

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant protection in the initial animal survival studies of Dengue virus infection. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

21 Jun 2010

DATATRAK International's Unified eClinical Solution showcased at annual DIA show

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry recently completed another successful showcase of its Unified eClinical Solution at the annual DIA show. DATATRAK's premier Solution coupled with the DATATRAK ONE business model are hallmarks of its singular technological vision and unwavering commitment to customers.

21 Jun 2010

Gamida Cell-Teva Joint Venture's StemEx program receives FDA Fast Track Designation

Gamida Cell announced today that the Gamida Cell-Teva Joint Venture has received an FDA Fast Track Designation for StemEx, in development as an alternative to a bone marrow transplant for patients with blood cancers such as leukemia and lymphoma.

21 Jun 2010

Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010

Immunomedics Inc. today announced that clinical trial results from the Phase IIb EMBLEM study of epratuzumab, a monoclonal antibody targeting CD22, in patients with moderate-severe systemic lupus erythematosus were presented at the 2010 annual Congress of the European League Against Rheumatism in Rome, Italy.

21 Jun 2010

Ostarine increases muscle mass and strength in postmenopausal women: Study

GTx, Inc. announced that Ostarine (GTx-024, formerly MK-2866) increased lean body mass and leg press strength in a head to head study evaluating Ostarine and another selective androgen receptor modulator, MK-3984, in postmenopausal women. The data were presented yesterday at the 2010 Annual Meeting of the Endocrine Society. GTx is developing its lead SARM, Ostarine, for the treatment of cancer induced muscle wasting (cancer cachexia).

21 Jun 2010

Aradigm announces $5 million private placement

Aradigm Corporation today announced that it has entered into a definitive agreement for the sale of common stock and warrants to three existing shareholders and one new investor in a private placement for aggregate gross proceeds of approximately $5 million. The closing of the private placement is subject to the satisfaction of customary closing conditions.

21 Jun 2010

Oxygen Biotherapeutics' common stock approved for secondary listing on SIX Swiss Exchange

Oxygen Biotherapeutics, Inc. announced today that its common stock has been approved for secondary listing on the SIX Swiss Exchange in addition to its listing on the NASDAQ Capital Market. Bank am Bellevue of Zurich is acting as the company's listing agent.

21 Jun 2010

Medical News

Emdeon's Assistant, Claim Master solutions earn HFMA Peer Reviewed designation

Saladax Biomedical, Bristol-Myers Squibb collaborate to develop clinical diagnostics

First StemSource Cell Bank in U.S. open

Dako, Omnyx partner to develop clinical algorithms for digital pathology

Simulations Plus third-quarter consolidated preliminary revenues up 14.9% to $3.1M

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

FDA grants Pathway 510(k) clearance for JETSTREAM G3 SF peripheral revascularization catheter for PVD

LIVALO for primary hyperlipidemia or mixed dyslipidemia now available in U.S.

AMRI board approves new $10 million share repurchase program

Electron cryomicroscopy helps observe molecules in hydrated state close to natural state

MDT aligned with AAP position statement on efforts to be made to save patient's natural dentition

Families of children with cancer are visiting Capitol Hill to seek more federal funding for cancer research

Antibacterial lab coats to help prevent spread of disease in hospitals

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

DATATRAK International's Unified eClinical Solution showcased at annual DIA show

Gamida Cell-Teva Joint Venture's StemEx program receives FDA Fast Track Designation

Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010

Ostarine increases muscle mass and strength in postmenopausal women: Study

Aradigm announces $5 million private placement

Oxygen Biotherapeutics' common stock approved for secondary listing on SIX Swiss Exchange

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News